The relation between the status of adaptive system and the number of postoperative complications in patients with gastrointestinal cancer: The effect of phenazepam
✍ Scribed by M. N. Ostroumova; N. N. Simonov; V. K. Kovalev; M. I. Bernstein
- Publisher
- John Wiley and Sons
- Year
- 1982
- Tongue
- English
- Weight
- 433 KB
- Volume
- 20
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The decrease in 11‐hydroxycorticosteroids concentration caused by 0.5 mg of dexamethasone administered at 11 pm was studied in 91 primary patients suffering from gastrointestinal cancer. In dexamethasone‐resistant patients postoperative complications developed in 65% of colon cancer patients and in 42% of stomach cancer patients. In dexamethasone‐sensitive patients the complications were observed in 24% and 12% of patients, correspondingly. The elevation of hypothalamic threshold of sensitivity to the inhibiting effect of glucocorticoids, revealed by the dexamethasone suppression test, was considered to be a result of a combined action of age, the tumor itself, and pronounced emotional stress during the preparation for operation. The derivative of benzodiazepin ‐ phenazepam ‐ when administered before the operation in colon cancer patients improved the results of the dexamethasone suppression test and decreased the number of postoperative complications.
📜 SIMILAR VOLUMES
## Abstract ## Background Discrepancies between pre‐ and postoperative diagnoses can lead to dilemma for operative management adequacy. ## Patients and Methods A total of 2,910 patients with gastric adenocarcinoma underwent curative surgery at the Samsung Medical Center between 2001 and 2003. Pa
## Abstract The authors studied 82 patients with rectal cancer who underwent radical surgical treatment at the N. N. Petrov Oncological Research Institute of the Ministry of Health of the USSR in 1974–1975. They defined the markedness of patients' psychogenic disturbances in the pre‐ and postoperat
## Abstract ## Background. Animal models suggest that cyclooxygenase‐2 (COX‐2) inhibitors may be beneficial in suppressing cancer cachexia. We investigated the effect of short‐course celecoxib on body composition, inflammation, and quality of life (QOL) in patients with cancer cachexia in a phase